These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 25682993)

  • 101. Combined diosmectite and mesalazine treatment for mild-to-moderate ulcerative colitis: a randomized, placebo-controlled study.
    Jiang XL; Wang HH; Cui HF
    Med Sci Monit; 2015 Jan; 21():163-70. PubMed ID: 25582578
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Adrenomedullin Therapy in Patients with Refractory Ulcerative Colitis: A Case Series.
    Ashizuka S; Inatsu H; Kita T; Kitamura K
    Dig Dis Sci; 2016 Mar; 61(3):872-80. PubMed ID: 26470867
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial.
    Sandborn WJ; Panés J; Zhang H; Yu D; Niezychowski W; Su C
    Gastroenterology; 2016 Jan; 150(1):96-102. PubMed ID: 26376350
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis.
    Jharap B; Sandborn WJ; Reinisch W; D'Haens G; Robinson AM; Wang W; Huang B; Lazar A; Thakkar RB; Colombel JF
    Aliment Pharmacol Ther; 2015 Nov; 42(9):1082-92. PubMed ID: 26381802
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort.
    Bossuyt P; Baert F; D'Heygere F; Nakad A; Reenaers C; Fontaine F; Franchimont D; Dewit O; Van Hootegem P; Vanden Branden S; Lambrecht G; Ferrante M;
    Inflamm Bowel Dis; 2019 Jan; 25(1):156-162. PubMed ID: 29920582
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Histologic improvement predicts endoscopic remission in patients with ulcerative colitis.
    Kim JE; Kim M; Kim MJ; Kim ER; Hong SN; Chang DK; Ha SY; Kim YH
    Sci Rep; 2024 Aug; 14(1):19926. PubMed ID: 39198522
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitis.
    Kawakami K; Inoue T; Murano M; Narabayashi K; Nouda S; Ishida K; Abe Y; Nogami K; Hida N; Yamagami H; Watanabe K; Umegaki E; Nakamura S; Arakawa T; Higuchi K
    World J Gastroenterol; 2015 Feb; 21(6):1880-6. PubMed ID: 25684955
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Oral tacrolimus for pediatric steroid-resistant ulcerative colitis.
    Navas-López VM; Blasco Alonso J; Serrano Nieto MJ; Girón Fernández-Crehuet F; Argos Rodriguez MD; Sierra Salinas C
    J Crohns Colitis; 2014 Jan; 8(1):64-9. PubMed ID: 23582736
    [TBL] [Abstract][Full Text] [Related]  

  • 109. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants.
    Reinisch W; Sandborn WJ; Panaccione R; Huang B; Pollack PF; Lazar A; Thakkar RB
    Inflamm Bowel Dis; 2013 Jul; 19(8):1700-9. PubMed ID: 23665965
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Histological inflammatory activity can predict endoscopic relapse in patients with ulcerative colitis who have achieved mucosal healing.
    González-Partida I; Martínez-Lozano H; González-Lois C; Peligros I; Sánchez-Yuste R; Salas I; Matallana V; Bighelli F; Calvo M; Marín-Jiménez I; Salas C; Vera MI; Menchén L; González-Lama Y
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e796-e802. PubMed ID: 34334707
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Optimising infliximab induction dosing for patients with ulcerative colitis.
    Dreesen E; Faelens R; Van Assche G; Ferrante M; Vermeire S; Gils A; Bouillon T
    Br J Clin Pharmacol; 2019 Apr; 85(4):782-795. PubMed ID: 30634202
    [TBL] [Abstract][Full Text] [Related]  

  • 112. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis.
    Arias MT; Vande Casteele N; Vermeire S; de Buck van Overstraeten A; Billiet T; Baert F; Wolthuis A; Van Assche G; Noman M; Hoffman I; D'Hoore A; Gils A; Rutgeerts P; Ferrante M
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):531-8. PubMed ID: 25117777
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Adsorptive Depletion of Myeloid Lineage Leucocytes as Remission Induction Therapy in Patients with Ulcerative Colitis after Failure of First-Line Medications: Results from a Three-Year Real World, Clinical Practice.
    Iida T; Ikeya K; Kato M; Abe J; Yamamoto M; Watanabe F; Sugimoto K; Hanai H
    Digestion; 2017; 96(2):119-126. PubMed ID: 28796990
    [TBL] [Abstract][Full Text] [Related]  

  • 114. ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis.
    Herrlinger KR; Koc H; Winter S; Teml A; Stange EF; Fellermann K; Fritz P; Schwab M; Schaeffeler E
    Clin Pharmacol Ther; 2011 Mar; 89(3):422-8. PubMed ID: 21289623
    [TBL] [Abstract][Full Text] [Related]  

  • 115. [Long-term adalimumab therapy in ulcerative colitis in clinical practice: result of the Hungarian multicenter prospective study].
    Rutka M; Bálint A; Farkas K; Palatka K; Lakner L; Miheller P; Rácz I; Hegede G; Vincze Á; Horváth G; Szabó A; Nagy F; Szepes Z; Gábor Z; Zsigmond F; Zsóri Á; Juhász M; Csontos Á; Szűcs M; Bor R; Milassin Á; Molnár T
    Orv Hetil; 2016 May; 157(18):706-11. PubMed ID: 27106726
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan.
    Hibi T; Sameshima Y; Sekiguchi Y; Hisatome Y; Maruyama F; Moriwaki K; Shima C; Saniabadi AR; Matsumoto T
    Dig Liver Dis; 2009 Aug; 41(8):570-7. PubMed ID: 19211314
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Rectal tacrolimus in the treatment of resistant ulcerative proctitis.
    Lawrance IC; Copeland TS
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1214-20. PubMed ID: 18761706
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Clinical relevance of endoscopic assessment of inflammation in ulcerative colitis: Can endoscopic evaluation predict outcomes?
    Mohammed N; Subramanian V
    World J Gastroenterol; 2016 Nov; 22(42):9324-9332. PubMed ID: 27895420
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab.
    Magro F; Lopes SI; Lopes J; Portela F; Cotter J; Lopes S; Moreira MJ; Lago P; Peixe P; Albuquerque A; Rodrigues S; Silva MR; Monteiro P; Lopes C; Monteiro L; Macedo G; Veloso L; Camila C; Afonso J; Geboes K; Carneiro F;
    J Crohns Colitis; 2016 Dec; 10(12):1407-1416. PubMed ID: 27226417
    [TBL] [Abstract][Full Text] [Related]  

  • 120. The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients.
    Lobatón T; Bessissow T; De Hertogh G; Lemmens B; Maedler C; Van Assche G; Vermeire S; Bisschops R; Rutgeerts P; Bitton A; Afif W; Marcus V; Ferrante M
    J Crohns Colitis; 2015 Oct; 9(10):846-52. PubMed ID: 26116558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.